ARM Q3 2017 Quarterly Data Report

The Alliance for Regenerative Medicine's Q3 2017 Data Report details industry-specific statistics compiled from more than 843 cell therapy, gene therapy, tissue engineering and other regenerative medicine companies worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events and current legislative and regulatory priorities.

The Q3 2017 data report also features commentary from ARM’s recently held Cell and Gene Meeting on the Mesa, including insights from Bob Azelby, EVP and Chief Commercial Officer, Juno Therapeutics; Nick Colangelo, President and CEO, Vericel Corporation; and Pascal Touchon, SVP and Global Head, Cell and Gene, Novartis Oncology. 

ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trial numbers and clinical data events.

To view and download previously released data reports and ARM presentations, please click here.

To download the report, please fill out the form below.

The report includes standalone graphics highlighting key data points, available below. Please right-click on the desired file type (.jpg or .png) to save the image to your computer.

 

[.jpg]   [.png]

[.jpg]   [.png]

[.jpg]   [.png]

[.jpg]   [.png]

[.jpg]   [.png]

SaveSave

SaveSave